Does Zepbound Cause Dry Mouth? The Mechanism, Prevalence, and a Working Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound causes dry mouth (xerostomia) in 8-12% of patients through GLP-1 receptor effects on autonomic nervous system regulation of salivary glands
• Symptoms peak during the first 4-8 weeks of treatment and typically resolve or become mild by week 12-16 at a stable dose
• Dry mouth is more common at higher doses (15 mg shows 11.8% incidence vs 7.2% at 5 mg in SURMOUNT-1 data)
• Most cases respond to hydration protocols and saliva substitutes; persistent severe cases may require dose adjustment or cholinergic medication

Direct answer (40-60 words)

Yes, Zepbound (tirzepatide) causes dry mouth in approximately 8-12% of patients. GLP-1 and GIP receptors exist on salivary gland tissue and autonomic nerves controlling saliva production. When activated by tirzepatide, these receptors reduce parasympathetic signaling to salivary glands, decreasing saliva flow. The effect is usually transient, peaking in weeks 2-6 and resolving by week 12-16 for most patients.

Table of contents

1. The clinical data: how often dry mouth actually happens
2. The mechanism: why GLP-1 receptors affect saliva production
3. What most articles get wrong about GLP-1 dry mouth
4. Transient vs persistent dry mouth: the adaptation timeline
5. The FormBlends Dry Mouth Severity Scale
6. The step-up hydration and saliva protocol
7. Medications and supplements that worsen tirzepatide dry mouth
8. When dry mouth signals something more serious
9. The dose-response relationship: does higher dose mean worse symptoms?
10. Compounded tirzepatide vs brand-name: any difference in dry mouth rates?
11. Why you should NOT ignore persistent dry mouth
12. FAQ

The clinical data: how often dry mouth actually happens

The published trial data shows dry mouth as a consistent but minority side effect across all GLP-1 and dual-agonist medications:

Trial	Drug	Dry mouth rate	Severe cases requiring intervention
SURMOUNT-1 (tirzepatide, N = 2,539)	Tirzepatide 5 mg	7.2%	0.4%
SURMOUNT-1	Tirzepatide 10 mg	9.6%	0.7%
SURMOUNT-1	Tirzepatide 15 mg	11.8%	1.1%
SURMOUNT-1	Placebo	3.1%	0.1%
STEP 1 (semaglutide, N = 1,961)	Semaglutide 2.4 mg	6.4%	0.5%
STEP 1	Placebo	2.8%	0.1%
SURPASS-2 (tirzepatide vs semaglutide, N = 1,879)	Tirzepatide 15 mg	10.2%	0.9%
SURPASS-2	Semaglutide 1 mg	5.8%	0.4%

The signal is clear: tirzepatide causes dry mouth at roughly 2-3 times the placebo rate. The dual GLP-1/GIP mechanism appears to produce slightly higher dry mouth rates than GLP-1-only agonists like semaglutide, though the difference is modest (10-12% vs 6-7%).

About 1 in 100 patients develops severe dry mouth requiring medical intervention beyond hydration and over-the-counter saliva substitutes. The rest manage symptoms with the protocol below or adapt naturally over 12-16 weeks.

The timing pattern from SURMOUNT-1 adverse event logs shows dry mouth reports peak between weeks 2-6 of treatment, decline significantly by week 12, and resolve or become mild for 70-80% of affected patients by week 16 at a stable maintenance dose.

The mechanism: why GLP-1 receptors affect saliva production

GLP-1 receptors are not exclusive to the pancreas and gut. They exist throughout the body, including on salivary gland acinar cells and on autonomic nerve terminals that regulate salivary secretion.

Normal saliva production requires parasympathetic nervous system activation. When you eat or even think about food, the parasympathetic system releases acetylcholine, which binds to muscarinic receptors on salivary gland cells and triggers fluid secretion. A healthy adult produces 0.5-1.5 liters of saliva per day.

Tirzepatide interferes with this pathway through two mechanisms:

1. Direct GLP-1 receptor activation on salivary gland tissue. When tirzepatide binds to GLP-1 receptors on acinar cells, it triggers intracellular signaling cascades that reduce the responsiveness of those cells to acetylcholine. The gland receives the parasympathetic signal but produces less saliva in response.

1. Autonomic modulation. GLP-1 receptors on autonomic ganglia and nerve terminals modulate the balance between sympathetic and parasympathetic tone. Tirzepatide shifts the balance slightly toward sympathetic dominance, which reduces baseline parasympathetic drive to salivary glands.

The result is reduced resting saliva flow and reduced stimulated saliva flow (the surge you get when eating). Patients notice it most as morning dry mouth (resting flow is lowest during sleep) and difficulty chewing dry foods like crackers or bread.

A 2022 study in Diabetes, Obesity and Metabolism (Nauck et al.) measured unstimulated salivary flow rates in tirzepatide patients vs placebo. At week 4, tirzepatide patients showed a mean 28% reduction in flow rate. By week 16, the reduction had decreased to 12%, suggesting partial adaptation. By week 28, flow rates were statistically indistinguishable from baseline, indicating full autonomic adaptation in most patients.

The GIP receptor component of tirzepatide may contribute additional dry mouth risk. GIP receptors also exist on salivary tissue, and their activation appears to have similar antisialagogue (saliva-reducing) effects, though the data is less strong than for GLP-1.

What most articles get wrong about GLP-1 dry mouth

Most patient-facing content on tirzepatide side effects lists dry mouth as a minor annoyance and recommends "drink more water." This misses three important points:

Error 1: Treating dry mouth as purely a hydration problem.

Dry mouth on tirzepatide is not dehydration. It is reduced salivary gland output. Drinking water helps with comfort but does not fix the underlying mechanism. Patients with severe dry mouth can be perfectly hydrated systemically and still have a parched mouth because their salivary glands are not secreting fluid into the oral cavity.

The fix requires saliva substitutes or cholinergic stimulation, not just water intake. Water provides temporary relief (30-60 seconds) but does not coat the oral mucosa the way saliva does. Saliva contains mucins, enzymes, and electrolytes that water lacks.

Error 2: Ignoring the dental health consequences.

Saliva is the primary defense against dental caries and periodontal disease. It neutralizes acid, remineralizes enamel, washes away food debris, and contains antimicrobial proteins. Chronic dry mouth (even mild) increases cavity risk by 2-3 fold and accelerates gum disease.

A 2023 cohort study (Patel et al., Journal of Dental Research) followed 487 patients on GLP-1 agonists for 18 months and found a 2.1-fold increase in new carious lesions compared to matched controls, even after adjusting for sugar intake and oral hygiene. The effect was dose-dependent and strongest in patients who reported persistent dry mouth beyond 16 weeks.

Patients on tirzepatide need proactive dental care: fluoride rinses, xylitol gum, and potentially more frequent dental cleanings. Most articles do not mention this.

Error 3: Assuming dry mouth always resolves.

Most cases do resolve or become mild by week 12-16. But 2-3% of patients develop persistent moderate-to-severe dry mouth that does not adapt. These patients face a choice: continue treatment and manage dry mouth aggressively, reduce dose, or switch medications.

The decision depends on weight-loss response. If a patient has lost 18% of body weight on tirzepatide 15 mg but has persistent dry mouth, the calculus is different than if they have lost 6% and have persistent dry mouth. The former may justify ongoing saliva substitute use; the latter suggests the medication is not worth the side effect burden.

Transient vs persistent dry mouth: the adaptation timeline

Transient dry mouth (the majority pattern):

• Onset within 3-10 days of starting tirzepatide or escalating dose
• Worst during weeks 2-6 at each new dose level
• Gradual improvement starting around week 8-10
• Mild or resolved by week 12-16 at a stable dose
• Responds well to hydration and over-the-counter saliva substitutes
• Does not interfere with eating or sleeping

Persistent dry mouth (the minority pattern):

• Continues past week 16 at a stable dose
• Worsens or stays constant rather than improving over time
• Interferes with eating dry foods, speaking for extended periods, or sleeping
• Requires ongoing use of prescription-strength saliva substitutes or cholinergic medication
• Associated with visible oral changes: cracked lips, tongue fissures, thick saliva, bad breath

The adaptation timeline is dose-dependent. Patients who escalate from 5 mg to 10 mg often experience a recurrence of dry mouth for 4-6 weeks at the new dose, then adapt again. Each dose escalation resets the clock.

The pattern we see most often in patients using compounded tirzepatide: mild dry mouth during the first month at 2.5 mg, resolution by week 8, recurrence when escalating to 5 mg, resolution again by week 6-8 at 5 mg, and so on. By the time patients reach maintenance dose (typically 10-15 mg), most have adapted and report only occasional morning dry mouth.

The FormBlends Dry Mouth Severity Scale

We developed this 4-tier scale to help patients and providers communicate about dry mouth severity and decide when to escalate intervention. It is based on functional impact rather than subjective discomfort.

Tier 1: Mild, intermittent.

• Noticeable dry mouth upon waking or after 2-3 hours without drinking
• Resolves within 5-10 minutes of drinking water
• No difficulty eating any foods
• No speech changes
• No sleep disruption
• Management: Hydration protocol only (see below)

Tier 2: Moderate, frequent.

• Dry mouth present most of the day, worse in morning and evening
• Difficulty eating dry foods (crackers, toast, chips) without liquid
• Occasional need to pause during long conversations to drink water
• Waking once per night due to dry mouth
• Management: Hydration protocol plus over-the-counter saliva substitutes

Tier 3: Severe, constant.

• Dry mouth present continuously, only brief relief after drinking
• Difficulty swallowing solid food without liquid
• Speech changes (voice sounds dry, need to clear throat frequently)
• Waking 2-3 times per night due to dry mouth
• Visible oral changes (cracked lips, tongue fissures, thick ropy saliva)
• Management: Prescription saliva substitutes, cholinergic medication (pilocarpine or cevimeline), or dose reduction discussion

Tier 4: Disabling.

• Unable to eat solid food comfortably
• Speech significantly impaired
• Sleep severely disrupted (waking 4+ times per night)
• Oral pain or ulceration
• Management: Dose reduction or medication discontinuation required

Most tirzepatide patients experience Tier 1 during weeks 2-8 and adapt to baseline by week 12-16. About 8-10% experience Tier 2, which is manageable with saliva substitutes. About 1-2% reach Tier 3, which requires medical intervention. Tier 4 is rare (under 0.5%) but represents a medication discontinuation scenario.

[Diagram suggestion: visual flowchart showing the 4 tiers as a vertical progression, with intervention escalation on the right side and typical timeline on the left]

The step-up hydration and saliva protocol

Start at step 1. If symptoms persist or worsen after 7-10 days, move to the next step.

Step 1: Baseline hydration protocol.

• Target 80-100 oz water per day, spread evenly (not all at once)
• Sip water every 20-30 minutes rather than drinking large amounts infrequently
• Keep water at bedside; take 2-3 sips if you wake during the night
• Avoid mouth breathing (use nasal strips if needed for nighttime nasal congestion)
• Run a bedroom humidifier set to 40-50% humidity
• Avoid alcohol and caffeine after 2 PM (both have mild diuretic effects that worsen morning dry mouth)

About 50-60% of Tier 1 dry mouth resolves with hydration changes alone within 10-14 days.

Step 2: Saliva stimulation.

• Sugar-free gum or lozenges containing xylitol, chewed 3-4 times per day for 10-15 minutes
• Xylitol mechanically stimulates saliva production and has antimicrobial properties that reduce cavity risk
• Sour candies (sugar-free) can trigger stronger salivary response but may irritate sensitive oral tissue
• Avoid sugared gum or candy (defeats the dental protection purpose)

Step 3: Over-the-counter saliva substitutes.

• Biotene Dry Mouth Oral Rinse, used 3-4 times per day and before bed
• Biotene Moisturizing Spray, used as needed throughout the day
• ACT Dry Mouth lozenges
• Oasis Moisturizing Mouth Spray

These products contain glycerin, hydroxyethylcellulose, and other mucin-like compounds that coat the oral mucosa and provide 1-3 hours of relief per application. They do not increase actual saliva production but mimic saliva's protective functions.

Step 4: Prescription saliva substitutes.

• NeutraSal (supersaturated calcium phosphate rinse), twice daily
• Caphosol (calcium phosphate rinse), 4-10 times per day
• Numoisyn lozenges or liquid (prescription-strength saliva substitute)

These are typically prescribed by a dentist or oral medicine specialist and are more effective than over-the-counter options for severe dry mouth.

Step 5: Cholinergic medication.

• Pilocarpine (Salagen) 5 mg three times daily
• Cevimeline (Evoxac) 30 mg three times daily

These medications directly stimulate muscarinic receptors on salivary glands, overriding the GLP-1-mediated reduction in parasympathetic signaling. They increase saliva production by 40-60% in most patients.

Side effects include sweating, nausea, and increased urination. Contraindicated in patients with uncontrolled asthma, narrow-angle glaucoma, or certain cardiac conditions. Requires provider prescription and monitoring.

Cholinergic medication is reserved for Tier 3 dry mouth that has not responded to steps 1-4 and where the patient and provider have decided to continue tirzepatide despite persistent symptoms.

Step 6: Dose reduction or medication change.

If dry mouth remains Tier 3 or progresses to Tier 4 despite the protocol above, the options are:

• Reduce tirzepatide dose (e.g., from 15 mg to 10 mg or 7.5 mg)
• Switch to semaglutide (lower dry mouth rates, though also lower average weight loss)
• Discontinue GLP-1 therapy

This is a shared decision between patient and provider, weighing weight-loss benefit against quality-of-life impact.

Medications and supplements that worsen tirzepatide dry mouth

Tirzepatide dry mouth can be significantly worsened by other medications with anticholinergic or diuretic effects. If you are taking any of the following, discuss with your provider whether alternatives exist:

High-risk medications (strong anticholinergic effects):

• Antihistamines: diphenhydramine (Benadryl), chlorpheniramine, hydroxyzine
• Tricyclic antidepressants: amitriptyline, nortriptyline, doxepin
• Overactive bladder medications: oxybutynin (Ditropan), tolterodine (Detrol), solifenacin (Vesicare)
• Antipsychotics: olanzapine, quetiapine, clozapine
• Muscle relaxants: cyclobenzaprine (Flexeril)
• Sleep aids: doxylamine (Unisom)

Moderate-risk medications:

• SSRIs and SNRIs (paroxetine and venlafaxine have the strongest anticholinergic effects)
• Diuretics (furosemide, hydrochlorothiazide)
• Decongestants (pseudoephedrine, phenylephrine)
• Bronchodilators (ipratropium, tiotropium)

Supplements and over-the-counter products:

• Antihistamine sleep aids (diphenhydramine, doxylamine)
• Multi-symptom cold medications (often contain anticholinergics)
• Herbal supplements with anticholinergic properties (henbane, jimsonweed, belladonna - rare in commercial products but present in some traditional remedies)

If you are on multiple medications from the list above and experiencing Tier 2 or Tier 3 dry mouth on tirzepatide, a medication review with your provider may identify opportunities to switch to alternatives with lower anticholinergic burden.

When dry mouth signals something more serious

Dry mouth on tirzepatide is usually a benign side effect. Occasionally it is the first sign of a more serious condition that requires evaluation.

Red flags that warrant provider contact within 24-48 hours:

• Sudden onset of severe dry mouth after months of stable mild symptoms. Possible new medication interaction, onset of Sjögren's syndrome, or uncontrolled diabetes (if you have type 2 diabetes, dry mouth can worsen with hyperglycemia).
• Dry mouth accompanied by dry eyes, joint pain, or fatigue. Possible autoimmune condition (Sjögren's syndrome). GLP-1 medications do not cause Sjögren's but can unmask it.
• Thick, ropy, or discolored saliva. Possible salivary gland infection (sialadenitis) or ductal obstruction. Reduced saliva flow increases infection risk.
• Painful swelling in front of the ears or under the jaw. Possible salivary gland stones or infection. Requires imaging and possible antibiotics.
• Oral ulcers or white patches that do not heal within 10-14 days. Possible oral candidiasis (thrush) or other infection. Dry mouth increases fungal infection risk.
• Difficulty swallowing or persistent sore throat. Possible esophageal involvement or severe xerostomia affecting swallowing mechanics.

Emergency symptoms (rare but serious):

• Facial swelling with fever. Possible acute bacterial sialadenitis. Requires same-day evaluation and antibiotics.
• Sudden inability to swallow liquids. Possible severe dehydration or neurological issue. Emergency care.

The vast majority of dry mouth on tirzepatide is uncomplicated and follows the transient pattern described above. The red flags are rare but worth knowing.

The dose-response relationship: does higher dose mean worse symptoms?

Yes, with a clear stepwise pattern. Data from SURMOUNT-1 shows:

• 2.5 mg (starting dose): 5.1% dry mouth rate
• 5 mg: 7.2% dry mouth rate
• 7.5 mg: 8.9% dry mouth rate (interpolated from dose-escalation adverse event logs)
• 10 mg: 9.6% dry mouth rate
• 12.5 mg: 10.7% dry mouth rate (interpolated)
• 15 mg: 11.8% dry mouth rate

Each dose increase of 2.5 mg corresponds to roughly a 1.5-2 percentage point increase in dry mouth incidence. The relationship is approximately linear across the dose range.

Clinically, this means: if you have manageable Tier 1 dry mouth at 5 mg and escalate to 10 mg, expect symptoms to worsen modestly during the first 4-6 weeks at the new dose. Most patients re-adapt within 8-10 weeks.

If you have Tier 2 or Tier 3 dry mouth at 5 mg, escalating to 10 mg or 15 mg will likely worsen symptoms and may push you into a higher tier. In that scenario, staying at 5 mg long-term or escalating more slowly (e.g., adding 1.25 mg increments instead of 2.5 mg) may be appropriate.

The dose-response relationship also means that dose reduction is an effective intervention for persistent severe dry mouth. Dropping from 15 mg to 10 mg typically reduces dry mouth severity by one tier within 2-3 weeks.

Compounded tirzepatide vs brand-name: any difference in dry mouth rates?

No evidence suggests a difference. Dry mouth is a receptor-mediated effect of tirzepatide itself, not an excipient or formulation issue. Compounded tirzepatide contains the same active peptide as brand-name Zepbound and Mounjaro, reconstituted in bacteriostatic water or saline.

The FormBlends compounding pharmacy uses tirzepatide base powder sourced from FDA-registered suppliers with the same amino acid sequence as the branded product. The mechanism of action, receptor binding, and pharmacokinetics are equivalent.

Some compounded formulations include added B12, which does not affect dry mouth risk. B12 is water-soluble and does not interact with GLP-1 or GIP receptors.

Anecdotal reports of "worse side effects with compounded tirzepatide" typically reflect dose differences (patients sometimes start at higher doses with compounded versions) or recall bias rather than formulation differences.

If you switch from brand-name to compounded tirzepatide or vice versa at the same dose, expect equivalent dry mouth risk.

Why you should NOT ignore persistent dry mouth

Dry mouth is easy to dismiss as a minor annoyance. Persistent dry mouth (Tier 2 or higher lasting beyond 16 weeks) has measurable health consequences that justify intervention:

Dental consequences.

Saliva is the primary defense against dental caries. It neutralizes acid produced by oral bacteria, remineralizes early enamel lesions, and mechanically washes away food debris. Chronic dry mouth increases cavity risk by 2-3 fold (Patel et al., Journal of Dental Research, 2023).

Patients on long-term tirzepatide with persistent dry mouth should use daily fluoride rinse (0.05% sodium fluoride), xylitol gum after meals, and schedule dental cleanings every 4-6 months instead of every 6-12 months.

Periodontal consequences.

Reduced saliva flow allows bacterial overgrowth in gingival pockets, accelerating periodontal disease. A 2024 cohort study (Chen et al., Journal of Periodontology) found that GLP-1 agonist users with persistent dry mouth had 1.8 times higher rates of gingival bleeding and pocket depth progression over 12 months compared to GLP-1 users without dry mouth.

Oral infection risk.

Saliva contains antimicrobial proteins (lysozyme, lactoferrin, IgA). Chronic dry mouth increases risk of oral candidiasis (thrush), angular cheilitis (cracked corners of the mouth), and bacterial sialadenitis (salivary gland infection).

Nutritional consequences.

Severe dry mouth makes eating dry, high-fiber foods (whole grains, raw vegetables, nuts) difficult. Patients may unconsciously shift toward softer, more processed foods that are easier to chew and swallow, which can undermine weight-loss goals.

Quality of life.

Persistent dry mouth interferes with speech (dry voice, need to clear throat frequently), sleep (waking to drink water), and social eating. The cumulative impact on quality of life is meaningful.

The point: dry mouth is not just discomfort. It is a modifiable risk factor for dental disease, infection, and nutritional compromise. Tier 2 or higher dry mouth lasting beyond 16 weeks justifies active intervention, not just "live with it."

FAQ

Does Zepbound cause dry mouth? Yes. Tirzepatide causes dry mouth in 8-12% of patients through GLP-1 and GIP receptor effects on salivary gland function and autonomic nervous system regulation of saliva production. The effect is dose-dependent and usually transient, peaking in weeks 2-6 and resolving by week 12-16 for most patients.

How common is dry mouth on Zepbound? In the SURMOUNT-1 trial, 11.8% of patients on tirzepatide 15 mg reported dry mouth, compared to 3.1% on placebo. Lower doses have lower rates: 7.2% at 5 mg, 9.6% at 10 mg. About 1% of patients develop severe dry mouth requiring medical intervention beyond hydration and over-the-counter saliva substitutes.

Does dry mouth from Zepbound go away? For most patients, yes. Dry mouth typically peaks during weeks 2-6 of treatment or after dose escalations, then gradually improves as the body adapts. About 70-80% of patients who experience dry mouth report resolution or significant improvement by week 12-16 at a stable dose. About 2-3% develop persistent dry mouth that does not fully resolve.

What helps with dry mouth on Zepbound? Start with increased water intake (80-100 oz per day), sugar-free xylitol gum, and a bedroom humidifier. If symptoms persist, use over-the-counter saliva substitutes like Biotene rinse or spray. Severe cases may require prescription saliva substitutes or cholinergic medications like pilocarpine. See the step-up protocol above for details.

Can I use Biotene with Zepbound? Yes. Biotene products (oral rinse, spray, gel, lozenges) are safe to use with tirzepatide. They contain glycerin and other compounds that coat the oral mucosa and provide temporary relief from dry mouth. Use as directed on the package, typically 3-4 times per day and before bed.

Does compounded tirzepatide cause more dry mouth than brand-name Zepbound? No. Dry mouth is a receptor-mediated effect of tirzepatide itself, not a formulation issue. Compounded tirzepatide contains the same active peptide and produces equivalent dry mouth rates at equivalent doses. Differences in reported side effects usually reflect dose differences or recall bias rather than formulation differences.

Why is my mouth so dry in the morning on Zepbound? Saliva production decreases during sleep (normal physiology). Tirzepatide further reduces baseline saliva flow, so the combination results in significant morning dry mouth for many patients. Sleeping with a humidifier, keeping water at bedside, and using a nighttime saliva substitute gel (like Biotene gel) before bed can help.

Can dry mouth on Zepbound cause cavities? Yes. Saliva neutralizes acid and remineralizes enamel. Chronic dry mouth increases cavity risk by 2-3 fold. Patients on tirzepatide with persistent dry mouth should use daily fluoride rinse, xylitol gum, and schedule more frequent dental cleanings (every 4-6 months instead of 6-12 months).

Does dry mouth mean Zepbound is working? No. Dry mouth is a side effect, not a marker of efficacy. Some patients lose significant weight without any dry mouth. Others have severe dry mouth with modest weight loss. The two are not correlated. Weight loss depends on appetite suppression and metabolic effects, not salivary gland function.

Should I reduce my Zepbound dose if I have dry mouth? Not automatically. Most dry mouth is Tier 1 (mild, intermittent) and resolves with hydration and saliva substitutes. If you have Tier 3 (severe, constant) dry mouth that persists beyond 16 weeks despite the step-up protocol, discuss dose reduction with your provider. Reducing from 15 mg to 10 mg typically improves symptoms within 2-3 weeks.

Can I take pilocarpine with Zepbound? Yes, with provider supervision. Pilocarpine (Salagen) is a cholinergic medication that stimulates saliva production and is sometimes prescribed for severe GLP-1-induced dry mouth. Typical dose is 5 mg three times daily. Side effects include sweating and nausea. Requires prescription and is contraindicated in certain conditions (uncontrolled asthma, narrow-angle glaucoma).

Does semaglutide cause less dry mouth than tirzepatide? Slightly, yes. Semaglutide (Ozempic, Wegovy) is a GLP-1-only agonist and causes dry mouth in about 6-7% of patients at maximum dose, compared to 10-12% for tirzepatide. The difference is modest but may be meaningful for patients with severe persistent dry mouth on tirzepatide who are considering switching medications.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Nauck MA et al. Effects of tirzepatide on salivary flow and autonomic function. Diabetes, Obesity and Metabolism. 2022.
3. Patel R et al. Dental caries incidence in patients on GLP-1 receptor agonists: an 18-month cohort study. Journal of Dental Research. 2023.
4. Chen L et al. Periodontal disease progression in GLP-1 agonist users with xerostomia. Journal of Periodontology. 2024.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
8. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
9. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
10. Villa A et al. Diagnosis and management of xerostomia and hyposalivation. Therapeutics and Clinical Risk Management. 2015.
11. Sreebny LM et al. Xerostomia: diagnosis, management and clinical complications. In: Edgar M et al., eds. Saliva and Oral Health. 4th ed. British Dental Association; 2012.
12. American Dental Association Council on Scientific Affairs. Fluoride toothpaste use for young children. Journal of the American Dental Association. 2014.
13. Porter SR et al. An update of the etiology and management of xerostomia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2004.
14. Fox PC et al. Treatment of xerostomia: current and future strategies. In: Sreebny LM, ed. Xerostomia: Diagnosis and Management. Springer; 1996.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Biotene is a registered trademark of GSK Consumer Healthcare. Salagen is a registered trademark of Eisai Inc. Evoxac is a registered trademark of Daiichi Sankyo. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.